JP2016519659A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519659A5 JP2016519659A5 JP2016502225A JP2016502225A JP2016519659A5 JP 2016519659 A5 JP2016519659 A5 JP 2016519659A5 JP 2016502225 A JP2016502225 A JP 2016502225A JP 2016502225 A JP2016502225 A JP 2016502225A JP 2016519659 A5 JP2016519659 A5 JP 2016519659A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- use according
- independently
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000547 substituted alkyl group Chemical group 0.000 claims 46
- 150000001875 compounds Chemical class 0.000 claims 35
- 150000001204 N-oxides Chemical class 0.000 claims 31
- 150000002148 esters Chemical class 0.000 claims 31
- 239000002207 metabolite Substances 0.000 claims 31
- 239000000651 prodrug Substances 0.000 claims 31
- 229940002612 prodrug Drugs 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 31
- 239000012453 solvate Substances 0.000 claims 31
- 229910052739 hydrogen Inorganic materials 0.000 claims 30
- 125000001475 halogen functional group Chemical group 0.000 claims 25
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000004104 aryloxy group Chemical group 0.000 claims 11
- 206010003246 arthritis Diseases 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- KIWSYRHAAPLJFJ-DNZSEPECSA-N n-[(e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enyl]pyridine-3-carboxamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/CNC(=O)C1=CC=CN=C1 KIWSYRHAAPLJFJ-DNZSEPECSA-N 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 210000001612 chondrocyte Anatomy 0.000 claims 7
- 230000004069 differentiation Effects 0.000 claims 7
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 7
- -1 polymorph Substances 0.000 claims 7
- 230000006378 damage Effects 0.000 claims 6
- 210000001503 joint Anatomy 0.000 claims 6
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 4
- 101150065749 Churc1 gene Proteins 0.000 claims 4
- 102100038239 Protein Churchill Human genes 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 claims 3
- 206010060820 Joint injury Diseases 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 claims 2
- 101000693085 Homo sapiens Angiopoietin-related protein 3 Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 1
- 102000011727 Caspases Human genes 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims 1
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 claims 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 1
- 244000025272 Persea americana Species 0.000 claims 1
- 235000008673 Persea americana Nutrition 0.000 claims 1
- 108010009736 Protein Hydrolysates Proteins 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 claims 1
- 125000005012 alkyl thioether group Chemical group 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 125000005362 aryl sulfone group Chemical group 0.000 claims 1
- 125000005361 aryl sulfoxide group Chemical group 0.000 claims 1
- 150000004832 aryl thioethers Chemical class 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims 1
- 230000002648 chondrogenic effect Effects 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000005265 dialkylamine group Chemical group 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 108010068072 salmon calcitonin Proteins 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
- 235000005282 vitamin D3 Nutrition 0.000 claims 1
- 239000011647 vitamin D3 Substances 0.000 claims 1
- 229940021056 vitamin d3 Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794094P | 2013-03-15 | 2013-03-15 | |
| US61/794,094 | 2013-03-15 | ||
| PCT/US2014/026722 WO2014151953A1 (en) | 2013-03-15 | 2014-03-13 | Compounds and methods for inducing chondrogenesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519659A JP2016519659A (ja) | 2016-07-07 |
| JP2016519659A5 true JP2016519659A5 (enExample) | 2017-04-13 |
| JP6579623B2 JP6579623B2 (ja) | 2019-09-25 |
Family
ID=51528123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502225A Active JP6579623B2 (ja) | 2013-03-15 | 2014-03-13 | 軟骨形成を誘導するための化合物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10500210B2 (enExample) |
| EP (1) | EP2968330B1 (enExample) |
| JP (1) | JP6579623B2 (enExample) |
| KR (1) | KR102283996B1 (enExample) |
| CN (3) | CN105228626A (enExample) |
| AU (1) | AU2014236719B2 (enExample) |
| CA (1) | CA2904160C (enExample) |
| ES (1) | ES2900815T3 (enExample) |
| HK (1) | HK1224172A1 (enExample) |
| WO (1) | WO2014151953A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012129562A2 (en) * | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| HK1224172A1 (zh) | 2013-03-15 | 2017-08-18 | 加州生物医学研究所 | 用於诱导软骨形成的化合物和方法 |
| CN105294533A (zh) * | 2015-12-02 | 2016-02-03 | 宋彤云 | 一种治疗骨病的药物组合物 |
| MX2019005621A (es) * | 2016-11-14 | 2019-08-12 | Novartis Ag | Metodos y composiciones para el tratamiento del daño del cartilago y la artritis. |
| WO2018200411A1 (en) * | 2017-04-24 | 2018-11-01 | The California Institute For Biomedical Research | Methods for inducing chondrogenesis |
| JOP20190282A1 (ar) | 2017-06-09 | 2019-12-05 | Novartis Ag | مركبات وتركيبات لحث تكوّن الغضاريف |
| CN107056677A (zh) * | 2017-06-19 | 2017-08-18 | 常州大学 | 一种3‑烷基2,3‑二氢异吲哚啉酮衍生物的合成方法 |
| US11427542B2 (en) * | 2018-03-29 | 2022-08-30 | Elex Biotech, Inc. | Compounds for treatment of cardiac arrhythmias and heart failure |
| CN110937987B (zh) * | 2018-09-25 | 2022-09-06 | 深圳市灵兰生物医药科技有限公司 | 一种化合物的合成路线及在抗糖尿病药物制备领域的应用 |
| EP3867226A4 (en) * | 2018-10-15 | 2022-11-23 | Gero Pte. Ltd. | PFKFB3 INHIBITORS AND THEIR USES |
| CN109730999B (zh) * | 2018-12-28 | 2021-12-24 | 中山大学 | 噻唑苯甲酰胺衍生在制备抗骨质疏松、抗骨关节炎药物中的应用 |
| CN112004798A (zh) * | 2019-01-07 | 2020-11-27 | 江苏凯迪恩医药科技有限公司 | 一种苯甲酰胺类化合物、中间体、制备方法及应用 |
| US12281060B2 (en) * | 2019-04-02 | 2025-04-22 | The University Of Chicago | Remodilins for airway remodeling and organ fibrosis |
| AU2021321068B2 (en) * | 2020-08-05 | 2025-01-02 | Lg Chem, Ltd. | Use of caspase inhibitor for alleviating or treating osteoarthritis |
| CN114763347B (zh) * | 2021-01-15 | 2024-06-21 | 华东师范大学 | 一类用于诱导间充质干细胞向软骨分化的化合物及其应用 |
| CN114763346B (zh) * | 2021-01-15 | 2025-06-10 | 华东师范大学 | 一类用于诱导软骨形成的化合物及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1016623A (en) | 1911-09-06 | 1912-02-06 | Harry Haller Jr | Photographic-printing device. |
| CH489993A (de) | 1967-12-19 | 1970-05-15 | Ciba Geigy | Das Pflanzenwachstum regulierendes und phytocides Mittel |
| FR2059977A1 (enExample) | 1969-08-14 | 1971-06-11 | Socibre | |
| KR0143565B1 (ko) * | 1988-06-13 | 1998-07-15 | 사노 가즈오 | 피발산의 p-치환된 페닐 에스테르 유도체, 그의 제조 방법 및 이를 포함하는 조성물. |
| JPH0320253A (ja) * | 1988-06-13 | 1991-01-29 | Ono Pharmaceut Co Ltd | ピバル酸 ｐ―置換フェニルエステル誘導体、それらの製造方法およびそれらを有効成分として含有するエラスターゼ阻害剤 |
| JPH0959236A (ja) * | 1995-08-23 | 1997-03-04 | Dai Ichi Seiyaku Co Ltd | ベンズアミド化合物 |
| US5729014A (en) | 1996-07-11 | 1998-03-17 | Varian Associates, Inc. | Method for injection of externally produced ions into a quadrupole ion trap |
| AU754830C (en) * | 1997-05-22 | 2004-02-12 | G.D. Searle Llc | Substituted pyrazoles as p38 kinase inhibitors |
| US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6632961B1 (en) * | 1998-05-22 | 2003-10-14 | Abbott Laboratories | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
| AR035773A1 (es) | 2000-12-20 | 2004-07-14 | Bristol Myers Squibb Pharma Co | Compuestos diamino ciclico, composicion farmaceutica y su uso en la fabricacion de un medicamento util para modular la actividad de una quimioquina |
| JP2005194191A (ja) * | 2001-12-28 | 2005-07-21 | Ajinomoto Co Inc | 抗肥満薬、脂肪肝治療薬 |
| US7087604B2 (en) * | 2002-03-08 | 2006-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US7288538B2 (en) * | 2003-02-20 | 2007-10-30 | Encysive Pharmaceuticals, Inc. | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists |
| EP1626962B1 (en) | 2003-05-12 | 2007-02-28 | Pfizer Products Inc. | Benzamide inhibitors of the p2x7 receptor |
| US20080152640A1 (en) * | 2003-07-29 | 2008-06-26 | Peter Prehm | Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer |
| US7863317B2 (en) * | 2003-08-21 | 2011-01-04 | Bristol-Myers Squibb Company | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US7776869B2 (en) * | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| EP1820795A4 (en) | 2004-12-07 | 2010-10-20 | Toyama Chemical Co Ltd | NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT |
| KR100787131B1 (ko) * | 2006-07-04 | 2007-12-21 | 한국생명공학연구원 | Ｈｉｆ―１ 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물 |
| KR101511396B1 (ko) * | 2007-07-20 | 2015-04-13 | 추가이 세이야쿠 가부시키가이샤 | ｐ27 단백질 유도제 |
| ES2527948T3 (es) * | 2007-10-05 | 2015-02-02 | Sanofi-Aventis Deutschland Gmbh | Uso de N-fenilamidas de ácido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor |
| US8143269B2 (en) | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| PT2453921E (pt) | 2009-07-14 | 2015-09-25 | Novartis Ag | Diferenciação de células estaminais mesenquimais |
| CN103038232B (zh) * | 2010-05-26 | 2016-01-20 | 阿德弗里奥药品有限责任公司 | 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途 |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| HK1224172A1 (zh) | 2013-03-15 | 2017-08-18 | 加州生物医学研究所 | 用於诱导软骨形成的化合物和方法 |
| US9688689B2 (en) | 2014-05-13 | 2017-06-27 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
-
2014
- 2014-03-13 HK HK16107019.4A patent/HK1224172A1/zh unknown
- 2014-03-13 CN CN201480028421.3A patent/CN105228626A/zh active Pending
- 2014-03-13 KR KR1020157026707A patent/KR102283996B1/ko active Active
- 2014-03-13 CN CN201710295821.6A patent/CN107007587A/zh active Pending
- 2014-03-13 CA CA2904160A patent/CA2904160C/en active Active
- 2014-03-13 EP EP14770543.8A patent/EP2968330B1/en active Active
- 2014-03-13 JP JP2016502225A patent/JP6579623B2/ja active Active
- 2014-03-13 ES ES14770543T patent/ES2900815T3/es active Active
- 2014-03-13 CN CN202211717279.6A patent/CN116059196A/zh active Pending
- 2014-03-13 US US14/774,673 patent/US10500210B2/en active Active
- 2014-03-13 US US14/210,198 patent/US9452170B2/en active Active
- 2014-03-13 WO PCT/US2014/026722 patent/WO2014151953A1/en not_active Ceased
- 2014-03-13 AU AU2014236719A patent/AU2014236719B2/en active Active
-
2019
- 2019-11-15 US US16/685,555 patent/US11045476B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519659A5 (enExample) | ||
| IL275348B2 (en) | Carbamoyl cyclohexyl acids linked via n triazole as lpa antagonists | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| JP2015537020A5 (enExample) | ||
| MY194087A (en) | Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament | |
| EP4442695A3 (en) | 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders | |
| MX2018004364A (es) | Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso. | |
| ECSP066730A (es) | Compuestos y procedimientos para uso | |
| DOP2013000191A (es) | Derivados de heteroarilo como modulares de nachr alfa 7 | |
| UY29503A1 (es) | Derivados de amida sustituida y metodos de uso | |
| WO2012122340A8 (en) | Soluble guanylate cyclase activators | |
| BR112014029016A2 (pt) | derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| IN2014CN03803A (enExample) | ||
| BR112014008412A2 (pt) | derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral | |
| NZ721645A (en) | Compounds for use as gpr120 agonists | |
| WO2013096429A3 (en) | Methods and compositions for reducing body fat and adipocytes | |
| CL2016000816A1 (es) | Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras. | |
| BR112022001568A2 (pt) | Composto, método para preparação do composto, composição farmacêutica, e, uso do composto | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| PH12013501117A1 (en) | Novel compound and medical use thereof | |
| JP2015502371A5 (enExample) | ||
| UY32435A (es) | 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona útil en el tratamiento de enfermedades pulmonares | |
| NI200900161A (es) | Sales de adición de ácido, hidratos y polimorfos de la etil - amida del ácido 5 - (2,4 -dihidroxi -5- isopropil - fenil) -4- (4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas. | |
| UY28896A1 (es) | Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros | |
| MX2020002432A (es) | Composicion farmaceutica. |